Noxopharm Ltd (NOX)

Currency in AUD
0.091
-0.002(-2.15%)
Closed·
NOX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.0910.094
52 wk Range
0.0430.135
Key Statistics
Bid/Ask
0.091 / 0.093
Prev. Close
0.093
Open
0.094
Day's Range
0.091-0.094
52 wk Range
0.043-0.135
Volume
22.54K
Average Volume (3m)
221.49K
1-Year Change
106.8182%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NOX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Short term obligations exceed liquid assets

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Feb 27, 2026
EPS / Forecast
-0.01 / --
Revenue / Forecast
1.73M / --
EPS Revisions
Last 90 days

NOX Income Statement

Compare NOX to Peers and Sector

Metrics to compare
NOX
Peers
Sector
Relationship
P/E Ratio
−5.2x−4.6x−0.4x
PEG Ratio
0.04−0.030.00
Price/Book
−25.3x1.9x2.6x
Price / LTM Sales
8.4x16.2x3.0x
Upside (Analyst Target)
-136.7%51.9%
Fair Value Upside
Unlock15.9%9.1%Unlock

Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company also develops orphan drug designations to treat less common disease; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. The company was incorporated in 2015 and is based in Glenhaven, Australia.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
0.000.00%0.00
Other Institutional Investors
14.19M4.62%1.36M
Public Companies & Retail Investors
293.05M95.38%27.99M
Total
307.24M100.00%29.34M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Rgt Capital Fund No 5 (Noxo) Pty Ltd2.12%6,500,333621
Nora Goodridge Investments Pty Ltd1.01%3,090,489295

FAQ

What Is the Noxopharm (NOX) Stock Price Today?

The Noxopharm stock price today is 0.091 AUD.

What Stock Exchange Does Noxopharm Trade On?

Noxopharm is listed and trades on the Sydney Stock Exchange.

What Is the Stock Symbol for Noxopharm?

The stock symbol for Noxopharm is "NOX."

What Is the Noxopharm Market Cap?

As of today, Noxopharm market cap is 28.880M AUD.

What Is Noxopharm's Earnings Per Share (TTM)?

The Noxopharm EPS (TTM) is -0.019.

From a Technical Analysis Perspective, Is NOX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Noxopharm Stock Split?

Noxopharm has split 1 times.

What is the current trading status of Noxopharm (NOX)?

As of Jul 10, 2026, Noxopharm (NOX) is trading at a price of 0.091 AUD, with a previous close of 0.093 AUD. The stock has fluctuated within a day range of 0.091 AUD to 0.094 AUD, while its 52-week range spans from 0.043 AUD to 0.135 AUD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.